Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-*trans* retinoic acid and chemotherapy

Hideho Henzan¹ · Ken Takase² · Tomohiko Kamimura³ · Yasuo Mori⁴ · Goichi Yoshimoto⁴ · Hiromi Iwasaki² · Koji Nagafuji⁵ · Ryosuke Ogawa⁶ · Tetsuya Eto¹ · Naoyuki Uchida⁷ · Tomoaki Fujisaki⁸ · Koji Kato⁴ · Mariko Minami^{2,4} · Yoshikane Kikushige⁴ · Koichi Akashi⁴ · Toshihiro Miyamoto⁴ · for the Fukuoka Blood & Marrow Transplantation Group (FBMTG)

Published online: 8 July 2020
© Japanese Society of Hematology 2020

Correction to: International Journal of Hematology
<https://doi.org/10.1007/s12185-020-02911-z>

In the original publication of the article, the “CNS involvement” in the last row under the column “*N*=50” has been published incorrectly. The correct Table 1 is given in this correction.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s12185-020-02911-z>.

✉ Toshihiro Miyamoto
toshmiya@intmed1.med.kyushu-u.ac.jp

- ¹ Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
- ² Department of Hematology, National Kyushu Medical Center, Fukuoka, Japan
- ³ Department of Hematology, Harasanshin Hospital, Fukuoka, Japan
- ⁴ Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
- ⁵ Department of Hematology, Kurume University Hospital, Kurume, Japan
- ⁶ Department of Hematology, Japan Community Health Care Organization Kyushu Hospital, Kita-Kyushu, Japan
- ⁷ Department of Hematology, Toranomon Hospital, Tokyo, Japan
- ⁸ Department of Hematology, Matsuyama Red Cross Hospital, Ehime, Japan

Table 1 Background patient characteristics and summary of induction therapy

	Total <i>N</i> = 50	Low risk (<i>N</i> = 27)	High risk (<i>N</i> = 23)	<i>P</i>
Age (range), years	45 (18–65)	44 (18–65)	45 (19–63)	0.83*
Male/female	24/26	13/14	11/12	1**
WBC at diagnosis, $\times 10^9/\text{L}$	2.1 (0.2–97.8)	0.9 (0.2–2.3)	16.8 (3.6–97.8)	<0.001*
Platelet at diagnosis, $\times 10^9/\text{L}$	32 (6–170)	42 (6–170)	25 (11–74)	0.0185*
<i>PML-RARA</i> , $\times 10^5/\mu\text{gRNA}$	2.2 (0.21–42.0)	2.1 (0.21–28.0)	2.3 (0.21–42.0)	0.922*
PT (range), sec, normal range 10–14	15.7 (8.0–89.9)	13.6 (11.2–89.9)	17.8 (8.0–71.8)	<0.001*
APTT (range), sec, normal range 24–39	29.5 (21–281)	28.9 (22.8–120)	29.6 (21–281)	0.444*
DIC				
Yes	43	21	22	0.107**
No	7	6	1	
Additional cytogenetic abnormality				
Yes	13	8	5	0.721**
No	37	19	18	
CNS involvement				
Yes	1	0	1	0.46**
No	49	27	22	

WBC white blood cell, PT prothrombin time, APTT activated partial thromboplastin time, DIC disseminated intravascular coagulation, CNS central nervous system

*Mann–Whitney *U* test

**Fisher's exact test